U.S. markets open in 8 hours 30 minutes

Veru Inc. (VERU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.22-0.29 (-3.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bottom Triangle

Bottom Triangle

Previous Close8.51
Open8.59
Bid0.00 x 2900
Ask0.00 x 900
Day's Range8.15 - 8.63
52 Week Range2.30 - 24.57
Volume770,832
Avg. Volume1,468,731
Market Cap654.999M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • These 4 Measures Indicate That Veru (NASDAQ:VERU) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That Veru (NASDAQ:VERU) Is Using Debt Reasonably Well

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients
    Benzinga

    Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients

    Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer patients. Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting. In the overall Phase 2 study, the presence and the amount of AR receptor expression in breast cancer tissue correlated with a beneficial antitumor response. The best overall target lesion reduction of

  • Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19
    Benzinga

    Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19

    Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients. Sabizabulin an oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties. The 300-subject trial is evaluating daily oral doses of 9mg sabizabulin for up to 21 days versus placebo. Subjects in the sabizabulin and placebo arms will also be allowed to receive standard of care. The primary efficacy endpoint will be the proportion of patients that die on study up to Day 60. Secondary endpoints will include the proportion of patients without respiratory failure, days in ICU, Clinical Improvement, days on mechanical ventilation, days in the hospital, and viral load. Enrollment is targeted to be completed by year-end. Price Action: VERU shares are down 1.50% at $7.90 on the last check Wednesday. Related content: Benzinga's Full FDA Calendar See more from BenzingaClick here for options trades from BenzingaVeru's FC2 Prescription Sales Boost Q2 Revenues© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.